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ABSTRACT 
Background: Cole-Carpenter syndrome (CCS) is commonly classified as a rare Osteogenesis 
Imperfecta (OI) disorder. This was following the description of two unrelated patients with 
very similar phenotypes who were subsequently shown to have a heterozygous missense 
mutation in P4HB.  
Objective(s): Here, we report a 3-year old female patient with severe OI who on exome 
sequencing was found to carry the same missense mutation in P4HB as reported in the 
original cohort. We discuss the genetic heterogeneity of CCS and underlying mechanism of 
P4HB in collagen production.  
Methods: We undertook detailed clinical, radiological and molecular phenotyping in addition, 
to analysis of collagen in cultured fibroblasts and electron microscopic examination in the 
patient reported here. 
Results: The clinical phenotype appears consistent in patients reported so far but 
interestingly, there also appears to be a definitive phenotypic clue (crumpling metadiaphyseal 
fractures of the long tubular bones with metaphyseal sclerosis which are findings that are 
uncommon in OI) to the underlying genotype (P4HB variant).  
Discussion: P4HB (Prolyl 4-hydroxylase, beta subunit) encodes for PDI (Protein Disulfide 
isomerase) and in cells, in its tetrameric form, catalyses formation of 4-hydroxyproline in 
collagen. The recurrent variant in P4HB, c.1178A>G, p.Tyr393Cys, sits in the C-terminal 
reactive centre and is said to interfere with disulphide isomerase function of the C-terminal 
reactive centre.  P4HB catalyses the hydroxylation of proline residues within the X-Pro-Gly 
repeats in the procollagen helical domain. Given the inter-dependence of extracellular matrix 
(ECM) components in assembly of a functional matrix, our data suggest that it is the 
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organisation and assembly of the functional ECM that is perturbed rather than the secretion of 
collagen type I per se.  
Conclusions: We provide additional evidence of P4HB as a cause of a specific form of OI- 
CCS and expand on response to treatment with bisphosphonates in this rare disorder. 
 
INTRODUCTION 
In 1987, Cole and Carpenter reported two unrelated infants with multiple fractures and 
deformities of bone, with a skeletal phenotype similar to severe osteogenesis imperfecta (OI).  
In addition, these patients also had proptosis, blue sclerae, hydrocephalus and a distinct facial 
gestalt.  They were reported to be of normal intelligence.
(1)
 Radiologically, these patients had 
characteristic skeletal manifestations including craniosynostosis, in addition to the 
deformities seen in severe progressive OI.   
Since the first description, there was only one further report of a patient with a similar 
phenotype 
(2)
 until Balasubramanian et al., 2015 described a 12-year old patient with 
phenotypic Cole-Carpenter syndrome (CCS) who had homozygous mutations in CRTAP and 
described CCS as a variant of recessive OI.
(3) 
This patient had the characteristic facial 
features, ocular proptosis, craniosynostosis (corrected in childhood) and severe bone fragility 
(needing treatment with bisphosphonates). In 2015, two reports were published describing the 
aetiology of CCS
(4,5)
: Rauch et al., described a heterozygous missense mutation in P4HB in 
the original cohort of patients; this came to be known as Cole-Carpenter syndrome 1 
(CLCRP1 OMIM #11240). Garbes et al., 2015 reported a German boy with phenotypic Cole-
Carpenter syndrome and 2 fetuses from terminated pregnancies with antenatal presentation of 
a severe bone fragility in a separate German family. All patients in this cohort were found to 
have compound heterozygous mutations in SEC24D. The authors described their presentation 
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to be overlapping with Cranio-lenticulo-sutural dysplasia (CLSD OMIM #607812) caused by 
mutations in a related COPII gene, SEC23A but summarised the phenotype to be more like 
CCS. This has now come to be known as Cole-Carpenter syndrome 2 (CLCRP2 OMIM 
#616294). Table 1 provides an overview of the clinical, radiological and molecular diagnosis 
of patients with CCS reported in the literature and this patient. 
Therefore, it appears that CCS is a genetically heterogeneous condition with a strikingly 
similar phenotype, common features being severe bone fragility and distinct facial 
dysmorphism with/ without craniosynostosis. The facial dysmorphism mainly comprises 
relative macrocephaly with wide open fontanelle, blue sclera, small nose, flat nasal bridge, a 
broad face with ocular proptosis. This is perhaps slightly different to the facial features 
characteristically seen in OI due to other genetic aetiology.  
Here we describe a 3-year old patient with severe bone fragility, who on exome sequencing, 
was shown to have the same missense mutation as described by Rauch et al., 2015. Reverse 
phenotyping suggested that this patient was likely to be in the CCS spectrum and functional 
studies were undertaken in hpf (human primary fibroblasts).  
 
CLINICAL REPORT 
The proband is the first child of healthy, non-consanguineous White, European parents with 
no significant family history. She has an older maternal half-brother who is fit and well. The 
pregnancy was unremarkable with no suggestions antenatally of bone fragility. She was born 
in a good condition at term with a birth weight of 3710 grams (z score 0.6). From one week 
of age, her oral intake reduced and she was noted to be irritable. She had multiple admissions 
for suspected urinary tract infection, however, her ultrasound scans of the renal tract, 
micturating cystourethrogram and DMSA scan were all normal. She was diagnosed with 
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positional talipes for which she received physiotherapy. At 6 months of age, she presented 
with a left distal tibial fracture. On clinical examination, she was noted to have failure to 
thrive (weight Z score reduced to -1.4), relatively large head with wide open fontanelle, blue 
sclera, small nose, flat nasal bridge, right upturned ear lobe, a broad face, long fingers, 
relatively broad thumbs and great toes (Figure 1a-c). A skeletal survey showed diffusely 
osteopenic bones with multiple vertebral body compression fractures in the thoracic and 
lumbar spine and fractures of the anterior left 8
th
, 9
th
 and 10
th
 ribs. She had Wormian bones 
over sagittal and lambdoid sutures noted on her skull radiograph and old fractures of both 
distal radial shafts. All long bones showed “crumpling” metaphyseal fractures with widening, 
sclerosis, and irregularity of the distal metaphyses (Figure 2a-e).  
A clinical diagnosis of osteogenesis imperfecta (OI) was made and she was commenced on 
intravenous bisphosphonate (pamidronate) infusions from 7 months of age, which she 
continues to receive at the current age of 3 years and 8 months. Until 2 years and 8 months of 
age, she had multiple non-traumatic fractures of long bones of her upper and lower limbs. 
Her vertebral fractures have, however, significantly improved with remodelling of all 
vertebral bodies. She had corrective tibial osteotomies and bilateral tibial rodding’s with 
Fassier–Duval lengthening rods at 2 years and 8 months of age and she is currently awaiting 
the surgical correction of deformities of her both femora and upper limb bones. 
Developmentally, she has progressed well with her speech and language and social skills. Her 
gross motor development has been delayed because of her limb bone deformities. 
At a recent Genetics review at 3-years of age, she was noted to be in a mainstream nursery 
and had not sustained any fractures in the last 18 months. She was wearing glasses for a 
squint and her teeth were noted to be brittle but with no evidence of dentinogenesis 
imperfecta. Her growth parameters were, weight 12.5 kilograms (Z score -1.84), height 77 
cms (Z score -4.99) and head circumference 54 cms (Z score +2.5); she was noted to have 
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frontal bossing with a broad face, flat nasal bridge, prominent eyes with bilateral low-set ears 
(Figure 1d) and bilateral limb deformities. 
Genetic testing prior to whole exome sequencing included targeted OI panel testing which at 
that time included all genes so far published in dominant and recessive OI (October 2014); 
dosage analysis of COL1A1/A2 genes using MLPA which was reported negative. She was 
subsequently recruited to a research study being undertaken in children with atypical OI with 
appropriate parental consent.  
 
MATERIALS AND METHODS 
This patient was recruited into a research project to study atypical forms of OI, to establish 
genotype: phenotype correlations. Funding was obtained from the Children’s Hospital 
Charity and ethical approval was obtained from the local regional ethics committee (REC 
reference: 15/YH/0362) to undertake phenotyping and genetic work-up in this group of 
patients.  
DNA sequencing and exome sequencing: 
Whole exome sequencing was performed using SureSelect QXT library preparation method 
and SureSelect Human All Exon V6 baits for target enrichment. Libraries were sequenced on 
a HiSeq 2500 using paired-end sequencing 2x100bp. Bcl2fastq (v1.8.4) was used to convert 
sequencing data to fastq files.  Fastq files were uploaded to Sapienta (v1.5.0) for mapping and 
variant calling. Sapienta does not provide a whole exome coverage summary; however, after 
mapping with bwa mem (0.7.15) to GRCh37, a mean exonic coverage of 103x (standard 
deviation 62.1) and a median of 94x was obtained. Bases contribute to coverage if their 
quality is >= 30 and mapping quality is at least 10 for the read within which they are 
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contained. Duplicate reads are excluded. “SureSelect Human All Exon V6 r2” design files 
were used to restrict coverage calculations; here we state values for the “Covered” bed file. 
Variants reported with a frequency > 1% in the NHLBI ESP or ExAC cohort populations 
were excluded. Further filtering of variants to look for potential loss of function changes 
(frameshift, splice site acceptor, splice site donor, or stop gained) was undertaken. Finally, a 
larger group of variants within a targeted gene list was assessed. The gene list consisted of 
those reported in connection with bone dysplasias, identified in GWAS studies of change in 
bone density, implicated in bone metabolism in mouse models, and genes with human 
phenotype ontology terms relating to increased susceptibility to fracture, totalling 
approximately 600 genes.  
Electron Microscopy from skin biopsy 
Electron microscopy (EM) of the skin ellipse biopsy specimen was performed by: fixing in 
3% phosphate buffered glutaraldehyde, post-fixation in 2% aqueous osmium tetroxide, 
processing to epoxy resin and at embedding, orientation to display sections of epidermis and 
full thickness dermis. Toluidine blue stained semi-thin sections (0.6um) were assessed by 
light microscopy, and thin sections (85nm) were cut on an ultramicrotome using a diamond 
knife, mounted on a 200 thin bar hexagonal mesh copper grid. The material was stained with 
uranyl acetate and lead citrate and 7 grid meshes were examined using a Philips 400 
transmission EM. Image capture and collagen fibril diameter quantitations were performed 
using an AMT 16 megapixel mid mount digital camera. The diameters of 301 unselected 
collagen fibrils, sectioned transversely, from 5 collagen bundles, at original magnification 
x20.000, in the mid reticular dermis, were measured. The diameters of 318 collagen bundles 
were measured, at original magnification x550.  The mean of the mean diameters, range, and 
deviation root mean squared (RMS) were calculated. In addition, collagen fibrils were 
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checked for the presence of collagen flowers, and fibroblasts were examined for expanded 
rER, and elastic fibres for structural abnormalities. 
Collagen analysis on cultured fibroblasts 
Primary patient-derived fibroblasts were cultured in Ham’s F10 supplemented with 12% fetal 
calf serum. Cells were grown for 72 hours on glass coverslips and incubated in the presence 
of 167 µM (50µg per ml) ascorbic acid for 0.5 or 24 hours, respectively, prior to fixation. 
Cells were fixed with 4% paraformaldehyde in PBS and processed for immunofluorescence 
using anti-collagen IαI (Novus Biologicals NB600-408) and imaged by confocal microscopy 
as described previously using an Alexa-Fluor-568-conjugated secondary antibody (Thermo 
Fisher Scientific), Prolong Diamond with DAPI for mounting and a Leica SP5 for analysis 
and image acquisition.
(6) 
Images were compared using automated segmentation of collagen 
fluorescence intensity using Volocity (version 6.3, Perkin Elmer). Statistical analysis was 
performed using an unpaired Student’s t-Test (p-values). 
For semi-quantitative analysis of COL1a1 levels in control and patient cells, cells were 
seeded confluent and grown for 24 hours. Subsequently, cells were incubated in serum free 
Ham’s F10 medium supplemented with or without 167 µM (50µg per ml) ascorbic acid for 
24 hours. The medium was collected, and the cells lysed for 15 minutes in buffer containing 
50mM Tris-HCl, 150mM NaCl, 1% (v/v) triton-X-100, 1% (v/v) protease inhibitor cocktail 
(Calbiochem) at pH 7.4 on ice. Protein fractions of medium and lysate were centrifuged at 
13500 rpm at 4 °C for 10 min. The cell pellet was discarded. The supernatant was denatured 
and run under reducing conditions on a 7% Tris-Acetate precast gel (NuPAGE ®) for 135 
min at 100V in Tris-Acetate running buffer supplemented with antioxidant. Transfer of 
protein bands onto a nitrocellulose membrane was performed at 15 V overnight. The 
membrane was blocked using 5% (w/v) milk powder in TBST for 30 minutes at RT and 
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incubated with antibodies against collagen IαI (Novus Biologicals NB600-408; rabbit, 1:500) 
and GAPDH (Thermo Fisher Scientific AM4300, mouse, 3:1000) as loading control for 1.5 
hours at RT. After repeated rinsing with TBST, the membrane was incubated for 1.5 hours at 
RT with HRP-conjugated antibodies diluted in the blocking solution (1:5000) against mouse 
and rabbit, respectively. The wash step was repeated, and detection was performed using 
Promega WB-ECL reaction reagents and autoradiography films with overnight exposure and 
subsequent development. 
 
RESULTS 
Genetic analysis:  
Exome sequencing identified a heterozygous c.1178A>G, p.Tyr393Cys pathogenic mutation 
in exon 9 of P4HB (NM_000918.3) (Figure 3). This mutation is predicted to replace tyrosine 
at position 393 with a cysteine; in silico analysis supports its likely pathogenicity. This result 
was confirmed by Sanger sequencing. DNA was only available from the mother and she 
tested negative for this mutation; the father’s sample was not available for analysis.  
Electron microscopy: 
Patient elastic tissue and fibroblasts were unremarkable with no collagen flowers seen (Figure 
4a). The mean collagen fibril diameter was 74nm, with a range from 39 to 95nm (RMS 
deviation 7 to 10nm) with a mean collagen bundle diameter of 3.3µ. These parameters were 
within the normal range for patient age. Adjacent to the sweat gland tubules, there were areas 
of small collections of individual collagen fibrils with proteoglycans wrapping around them 
(Figure 4b), the significance of which is uncertain. 
Collagen analysis: 
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Collagen deposited by patient fibroblasts in culture showed not statistically detectable 
differences (with a p-value of 0.76 for the quantified mid-intensity and 0.34 for high-intensity 
deposition) compared to controls (Figure 5). While there was a slight trend towards a steady-
state decrease in collagen secretion, at short times of incubation in the presence of ascorbic 
acid, we detected no differences in gross organisation or secretion of type 1 collagen.  
 
DISCUSSION 
P4HB (Prolyl 4-hydroxylase, beta subunit), also known as ‘Procollagen-proline 2-
oxoglutarate-4-dioxygenase, beta subunit (OMIM *176790) maps to chromosome 17q25.3 
and spans 18Kb with 10 exons (Pajunen et al., 1991). P4HB encodes for PDI (Protein 
Disulfide isomerase) and in nucleated cells, in its tetrameric form, assists in the formation of 
4-hydroxyproline in collagen by P4HA prolyl hydroxylase. It is likely that the recurrent 
missense mutation in P4HB results in a very specific form of bone fragility by interfering 
with collagen formation, which could conceivably be associated with additional changes in 
deposition and/or assembly of extracellular matrix (ECM).  
Cole-Carpenter syndrome [OMIM 112240] is mainly characterised by bone fragility, 
craniosynostosis, ocular proptosis, hydrocephalus and a distinctive facial appearance.  
Intelligence is reported to be normal.  In their original report, Cole and Carpenter described 
two patients
(1)
:  Patient 1 had multiple fractures, frontal bossing, proptotic appearance and 
progressive hydrocephalus.  Skeletal survey at 4-months of age showed numerous 
metaphyseal irregularities and compression fractures in the long bones.  Progressive 
craniosynostosis was noted at 9-months of age.  His voice was noted to be high-pitched, but 
words were reported to be well-formed.  Patient 2 had hypotonia and failure-to-thrive noted 
at 2-months of age and facial dysmorphism was noted including micrognathia, frontal 
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bossing and proptotic appearance.  A skeletal survey showed multiple metaphyseal 
compression fractures.  In the report, the authors concluded that both patients had a variant 
form of osteogenesis imperfecta, but with additional findings of multiple metaphyseal 
irregularities, craniosynostosis, hydrocephalus, ocular proptosis and a distinctive face that 
was not characteristic of any known syndromes with craniosynostosis or type of OI.  Both 
patients were reported to have normal neurological development (when reported Patient 1 
was 4 years and Patient 2 was 19 months of age). 
Rauch et al., 2015 described re-evaluation of these children as adults and reported both 
Patient 1 and 2 as using a wheelchair with severe scoliosis and marked limb deformities; 
treatment with intravenous pamidronate over the previous 12-months in Patient 1 and over 3 
years in Patient 2 had not altered their clinical status.
(4)
 The radiographs in that paper clearly 
show the additional effects of prolonged immobility in association with the severe bone 
disease, notably gracile long bones with popcorn epiphyses. WES on genomic DNA was 
performed on both patients which revealed the same heterozygous variant c.1178A>G, 
p.Tyr393Cys in exon 9 of P4HB. The mechanism pertaining to gain-of-function of mutant 
PDI protein was proposed and tested which has not been replicated in the current study. 
In this report, we identified the same missense mutation in another patient with severe OI 
who has clinical overlap with CCS and how this variant results in severe bone fragility. The 
obvious difference in our patient clinically is the age at which pamidronate was commenced 
(7-months) which appears to have ameliorated the phenotype with reduced fracture 
frequency, vertebral fracture incidence and reduced distress which she suffered in the first 
few months of life. This may be supportive of early benefits of commencing treatment in 
patients with CCS. 
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The clinical phenotype appears consistent in patients reported so far with CCS but 
interestingly, there also appears to be an emerging, distinctive radiological phenotype with 
what appears to be a definitive phenotypic clue to the underlying genotype (P4HB mutation). 
Figure 2 demonstrates metadiaphyseal ‘crumpling’ fractures with metaphyseal sclerosis in the 
long tubular bones, findings that are uncommon in OI and may be a pointer to the role in 
disease of this specific mutation. Patient 1 described by Cole and Carpenter also has the same 
metadiaphyseal compression fractures with irregular sclerosis and lucencies and subsequent 
bowing deformity (Figure 1 in Cole and Carpenter paper). Therefore, we propose that the 
metaphyseal ‘crumpling’ fractures with metaphyseal sclerosis may be a clue to the underlying 
genotype. This was dissimilar to the findings of osteopenia and bowing with fractures in 
radiographs of patient reported by Amor et al., 2000 who did not share similar radiological 
findings as described above and tested negative for the P4HB recurrent mutation.
(2)
 
Interestingly, reviewing the radiographs of the patient reported by Balasubramanian et al., 
2015 with phenotypic CCS who has homozygous variants in CRTAP, the metaphyseal 
compression fractures and sclerosis were not present, thus adding further evidence to this 
observation.
(3)
 
P4HB encodes the beta subunit of prolyl 4-hydroxylase which is a highly abundant multi-
functional enzyme belonging to the protein disulphide isomerase (PDI) family. The PDI 
family comprises PDI and PDI-like proteins with more than twenty members having been 
studied in humans.
(7)
 PDI is usually found in the endoplasmic reticulum (ER) but can also be 
released to function at the extracellular matrix or cell surface. PDI is the most abundant 
family member comprising 0.8% of total cellular protein in yeast and mammalian cells 
(8)
 and 
is critical for cell viability in yeast.
(9)
 It functions as a redox catalyst and as a chaperone by 
preventing protein aggregation in the ER or by retaining proteins within the ER where 
necessary.
(10)
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P4HB comprises four TRX-like (thioredoxin-like) domains termed a, b, b’, a’, a linker (x) 
and a C-terminal extension domain organised in the order of abb’xa’c. However, only two of 
these four domains (a and a’) have disulphide isomerase activity and are separated from each 
other by the enzymatically inactive b and b’ domains. P4H exists as a 2:2 stoichiometric 
heterotetramer and is generally called the α-subunit existing as three isoforms (α (I), α (II) 
and α (III). All three α subunits require a β-subunit i.e. PDI to form an enzymatically active 
complex. The PDI β-subunit is required to maintain the solubility of the P4H α subunit and 
keep the complex within the ER. As well as the disulphide isomerase activity, the tetrameric 
form is active in hydroxylation of proline residues within preprocollagen. Therefore, PDI as a 
stand-alone disulphide isomerase and as a P4H heterotetramer, is crucial for procollagen 
biosynthesis.
(11)
 
Hence, PDI family members function as molecular chaperones and as disulphide 
oxidoreductase/isomerases. As a result, they can make, break or rearrange disulphide bonds 
in client proteins, including collagen and extracellular matrix proteins. These disulphide 
bonds are essential to ensure the protein has structural stability and also to keep multimeric 
complexes together. Cellular function relies on the ability of proteins to adopt their correct 
folds and it is very well recognised that misfolded proteins are known to result in disease; this 
is especially true in OI.  However, it should be noted that the recurrent P4HB mutation 
reported here does not directly alter the catalytic CGHC motif of PDI. Rather, the mutation 
results in the gain of a cysteine residue, which may lead to a “gain of function” phenotype. In 
this scenario, PDI could either misoxidise, fail to interact appropriately with P4HA or interact 
inappropriately with other proteins through spurious inter-molecular disulphide bonds. 
The recurrent mutation in P4HB, c.1178A>G, p.Tyr393Cys, sits towards the C-terminus and 
is said to interfere with disulphide isomerase function.  P4HB catalyses the hydroxylation of 
proline residues within the X-Pro-Gly repeats in the procollagen helical domain. However, 
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our data indicates no major difference in extracellular collagen type I deposition by patient 
fibroblasts, as judged by immunofluorescence. While there was a minor trend towards an 
increase in extracellular collagen type I compared to the control, this was not statistically 
significant. Our experiments do not define whether this collagen is triple helical and we have 
not examined other collagen types or proteoglycans. Given the inter-dependence of ECM 
components in assembly of a functional matrix, our data suggest that it is possible that it is 
the organisation and assembly of the functional ECM that is perturbed rather than the 
secretion of collagen type I per se. We postulate that the defect might arise from overall 
changes in matrix composition or architecture. However, this will require further functional 
analysis of whole ECM, which is ongoing.  
PDI proteins have already been implicated in human disease and are said to have roles in 
haemostasis, infectious disease, lipid homeostasis, neurodegeneration, cancer and 
infertility
(12-16)
; we now know that it is also involved in bone disease (OI).  
In this report, we demonstrate that Cole Carpenter syndrome is caused by a recurrent P4HB 
mutation with a very specific clinical and radiological phenotype and provide further clues to 
the underlying genotype. We have shown that possibly P4HB acts on collagen synthesis not 
by affecting the global secretion of procollagen type I from cells but in maintaining a 
functional ECM.  
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FIGURE LEGENDS 
Figure 1a-d: Photographs of patient (frontal and profile) demonstrating frontal bossing, 
blueish grey sclerae, flat nasal bridge, prominent veins; limb deformities aged 6-months 
(Figure 1a-c) and aged 3 years (Figure 1d). 
Figure 2: Selected radiographs from a skeletal survey (aged 6 months) 
2a: AP right forearm 2b: AP left forearm 2c: AP right leg  
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There is generalised reduction in bone density with relative flaring of the metaphyses. There 
are slightly angulated and displaced transverse fractures at the junction of metaphyses and 
diaphyses of all imaged bones except the humeri. Note the irregular metaphyseal sclerosis at 
the fracture sites, but also of distal humerus and proximal radius and ulna, where there are no 
fractures. Symmetrical metadiaphyseal fractures of this nature are uncommon in OI. 
There is a further minimally displaced fracture of the shaft of the left radius (arrow).  
2d: Lateral spine: There are multiple vertebral compression fractures. 
Figure 2e: AP and lateral right femur (aged 10 months) 
Osteopenia, flared metaphyses and an acute metadiaphyseal junction fracture in a slightly 
more proximal position than the previous fracture. As in Figure 2a, note the irregular 
sclerosis around the healing fracture. Sclerosis (but no fractures) is also seen around the 
proximal tibial and fibular metaphyses. 
Figure 2f: Lateral right forearm, lateral right leg (aged 31 months) 
There is significant bowing deformity of the forearm and leg bones. The bones are dense, 
presumably due to bisphosphonate therapy (note bisphosphonate lines at distal radial and 
ulnar metaphyses and dense periphery of the tarsal bones). There are healing fractures of the 
right mid radial and distal humeral shafts. 
Figure 3: Sequencing electropherograms demonstrating a heterozygous c.1178A>G mutation 
predicted to result in a p.(Tyr393Cys) amino acid change was identified in the P4HB gene 
(NM_000918.3) (Figure 3b) and normal trace in mother (Figure 3a).   
Figure 4a-b: 4a: Electron microscopy demonstrating scattered small collagen fibrils within a 
bundle of unremarkable fibrous collagen. Original magnification x20,000; 4b: Proteoglycan 
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fibres wrapping around collagen fibrils. Original magnification x12, 000 (indicated by 
arrows). 
Figure 5a-d: Immunofluorescence and subsequent quantification of extracellular collagen I 
of control and patient-derived skin fibroblasts after 30 minutes (A-B) and 24 hours (C-D) of 
ascorbic acid-2-phosphate. 5.a-c: Maximum projection of Z-Stacks consisting of 24 slices 
with ∆z = 0.08 µm. Scale bar indicates 50 µm. 5.c/d: Quantification of 5.a and 5.c for mid-
intensity values (16-62% or 40-159; empty shapes) and high-intensity values (63-100% or 
160-255; filled shapes) for control (circles) and patient (squares). The mean is displayed in 
gray. Error bars show the standard deviation. 
Figure 5e: Western Blot showing COL1a1 levels in control and patient primary fibroblasts. 
Lanes show fractions of medium (M) and lysate (L) of control and patient cells incubated 
with (+), or without ascorbate acid (-) for 24h. Expected band size for COL1a1 monomer 
140kDa, dimer with COL1a2 270kDa, trimer 400kDa.  
Table1: Comparison of clinical, radiological and molecular diagnosis in patients reported 
with CCS with patient reported here. 
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Table 1: 
 This patient  Cole & 
Carpenter 
1987 Patient 
1  
Cole & 
Carpenter 
1987  
Patient 2 
Amor 2000 Balasubramanian 
2015 
Garbes 2015 
Patient 1 
Garbes 2015 Garbes 2015 
Age 3y 4y 18m 30m 12y 7y Fetus 1 Fetus 2 
Sex F M M F F M F F 
Ethnicity White White White White Asian German German German 
Consanguinity No No No No Yes No No No 
Molecular 
diagnosis 
P4HB 
c.1178A>G, 
p.Tyr393Cys 
P4HB 
c.1178A>G, 
p.Tyr393Cys 
(Rauch et al., 
2015) 
P4HB 
c.1178A>G, 
p.Tyr393Cys
(Rauch et al., 
2015) 
NK CRTAP 
c.118G>T,p.Glu40* 
SEC24D 
c.613C>T, 
p.Gln205*; 
c.3044C>T,p.S
er1015Phe 
SEC24D 
c.2933A>C, 
p.Gln978Pro 
(mat); 
c.3044C>T,p
.Ser1015Phe 
(pat) 
SEC24D 
c.2933A>C, 
p.Gln978Pro 
(mat); 
c.3044C>T,p.S
er1015Phe 
(pat) 
Prenatal 
Fractures 
- - - - - + ++ ++ 
Postnatal 
Fractures 
++ ++ ++ + ++ + NA NA 
Craniosynostosis - + - + + + NA NA 
Vertebral 
Fractures/ 
Scoliosis 
++ ++ ++ + ++ + NA NA 
MCF + + + - - - - NA 
Wormian bones + + - + + + NA NA 
BP Therapy + +? +? + + + NA NA 
Ocular proptosis + + + + + + NA NA 
Blue sclerae + + + + + + NA NA 
Macrocephaly + + + + + + NA NA 
Hydrocephalus - + + - - + NA NA 
DI - + - + + - NA NA 
Intelligence N N N N N N NA NA 
MCF: metaphyseal compression fractures; NA: Not available/ applicable; NK: Not known yet; ?+: Increase in BMD, no clinical response 
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